- Home
- GNS vs BRNS Comparison
GNS vs BRNS Comparison
Compare GNS & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNS | BRNS |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 30.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GNS | BRNS |
|---|---|---|
| Price | $0.15 | $0.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 3.0M | 99.0K |
| Earning Date | 03-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $156.26 | N/A |
| Revenue Next Year | $35.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.15 | $0.51 |
| 52 Week High | $1.06 | $1.83 |
Technical Indicators
Market Signals| Indicator | GNS | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 39.98 | 60.28 |
| Support Level | $0.15 | $0.65 |
| Resistance Level | $0.23 | $0.74 |
| Average True Range (ATR) | 0.01 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 9.36 | 66.07 |
Price Performance
Historical ComparisonAbout GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.